The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

There is concern that people with rheumatic disease, often treated with immunosuppressive
or immunomodulatory medication, may be at an increased risk of poor outcomes of novel …

The ongoing pandemic coronavirus disease 19 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is a matter of global concern …

This is a comment on" COVID-19, cytokines and immunosuppression: what can we learn
from severe acute respiratory syndrome?" Clin Exp Rheumatol. 2020 Mar-Apr; 38 (2): 337 …

Individuals with inflammatory rheumatic disease require special consideration with regard to
coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome …

Purpose of review The COVID-19 outbreak has resulted in uncertainty for patients with
autoimmune rheumatic diseases for several reasons. They are concerned about their risk of …

Since the outset of the COVID-19 pandemic, numerous risk factors for severe disease have
been identified. Whether patients with rheumatic diseases, especially those receiving …

Objectives The impact of rheumatic diseases on COVID-19 infection remains poorly
investigated. Here we performed a systematic review and meta-analysis to evaluate the …

Objective Rheumatic disease patients on certain immunomodulators are at increased risk of
impaired humoral response to SARS-CoV-2 vaccines. We aimed to identify factors …

The COVID-19 pandemic has already caused over 400 000 infections and led to over 17
000 deaths worldwide, dramatically disrupted daily life, and is placing extreme demands on …